Healthcare · Biotechnology · NASDAQ

Alumis Inc (ALMS) Stock Price, Analysis & Trade Signals

$5.60-0.53 (-8.65%)

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5…

ALMS key stats

Market Cap
$724.84M
P/E Ratio
0
EPS
-3.86
52 Week Range
$4.60 – $31.35
50-Day Avg
7.24
200-Day Avg
20.44
Revenue (TTM)
$7.4M
Revenue Growth (Qtr YoY)
-37.7%
Profit Margin
0%
Operating Margin (TTM)
-5744%
Beta
-0.27
Volume
1.49M
30-Day Avg Volume
1.91M
CEO
Martin Babler
Employees
224
IPO Date
Jun 28, 2024

ALMS analyst rating & price target

10 analysts rate ALMS Buy on consensus.

1Strong Buy
9Buy
0Hold
0Sell
0Strong Sell

Consensus price target: $39.40 (+603.57% upside from $5.60)

Recent ALMS insider transactions

InsiderDateTransactionSharesValue
Schroer John R.
Chief Financial Officer
Nov 2, 2026Sale794$5.18K
Hardiman Roy C.
Chief Business & Strategy Ofcr
Nov 2, 2026Sale652$4.25K
Bradley Mark Christopher
Chief Development Officer
Nov 2, 2026Sale623$4.06K
Drappa Jorn
Chief Medical Officer
Nov 2, 2026Sale593$3.87K
Pangali Sanam
Chief Legal Officer
Nov 2, 2026Sale332$2.16K

Alumis Inc annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$24.05M—$-243.33M
2024$0—$-294.23M
2023$0—$-154.99M

Stock data for ALMS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics